Pancreatic cancer-associated stroma production

American Journal of Surgery

Volumn 194, Issue 4 SUPPL., 2007, Pages

  Korc, Murray ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Growth factors; Heparan sulfate proteoglycans; Pancreatic cancer; Stroma; Targeted therapy; Tumor microenvironment

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FG 3019; FIBROBLAST GROWTH FACTOR; GLYPICAN 1; NERVE GROWTH FACTOR; PROTEOGLYCAN; SYNDECAN 1;

ARTICLE; CELL PROLIFERATION; FIBROBLAST; GENETIC ANALYSIS; HUMAN; PANCREAS CANCER; PANCREAS DUCT; PRIORITY JOURNAL; STELLATE CELL; STROMA;

ADENOCARCINOMA; ANIMALS; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION; GENES, RAS; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; STROMAL CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34648852355     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2007.05.004     Document Type: Article

References (34)

1. Gudjonsson B. Cancer of the pancreas: 50 years of surgery. Cancer 60 (1987) 2284-2303
2. Warshaw A.L., and Ferandez-Del Castillo C. Pancreatic carcinoma. N Engl J Med 326 (1992) 455-465
3. DiMagno E.P., Reber H.A., and Tempero M.A. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 117 (1999) 1464-1484
4. Sener S.F., Fremgen A., Menck H.R., et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 189 (1999) 1-7
5. Kornmann M., Beger H.G., and Link K.H. Chemosensitivity testing and test-directed chemotherapy in human pancreatic cancer. Recent Results Cancer Res 161 (2003) 180-195
6. Kern S., Tempero M., and Corley B. Pancreatic cancer: an agenda for action. Report of the Pancreatic Cancer Progress Review Group (2001), NCI, Bethesda, MD
7. Korc M. Biology of pancreatic cancer. In: Rustgi A.K., and Crawford J. (Eds). Gastrointestinal Cancers (2003), Saunders, Philadelphia, PA 519-528
8. Hansel D.E., Kern S.E., and Hruban R.H. Molecular pathogenesis of pancreatic cancer. Annu Rev Genomics Hum Genet 4 (2003) 237-256
9. Summy J.M., Trevino J.G., Baker C.H., et al. c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas 31 (2005) 263-274
10. Greten F.R., Weber C.K., Greten T.F., et al. Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 123 (2002) 2052-2063
11. Niu J., Li Z., Peng B., et al. Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells. J Biol Chem 279 (2004) 16452-16462
12. Hruban R.H., Wilentz R.E., and Kern S.E. Genetic progression in the pancreatic ducts. Am J Pathol 156 (2000) 1821-1825
13. Hezel A.F., Kimmelman A.C., and Stanger B.Z. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20 (2006) 1218-1249
14. Hruban R.H., Adsay N.V., Albores-Saavedra J., et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 66 (2006) 95-106
15. Hingorani S.R., Wang L., Multani A.S., et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7 (2005) 469-483
16. Aguirre A.J., Bardeesy N., Sinha M., et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17 (2003) 3112-3126
17. Bachem M.G., Schunemann M., Ramadani M., et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128 (2005) 907-921
18. Farrow B., Sugiyama Y., Chen A., et al. Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg 239 (2004) 763-769
19. Zhu Z., Kleeff J., Kayed H., et al. Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells. Mol Carcinog 35 (2002) 138-147
20. Sangai T., Ishii G., Kodama K., et al. Effect of differences in cancer cells and tumor growth sites on recruiting bone marrow-derived endothelial cells and myofibroblasts in cancer-induced stroma. Int J Cancer 115 (2005) 885-892
21. Kleeff J., Ishiwata T., Kumbasar A., et al. The cell-surface heparan sulfate proteoglycan glypican-1 is an important regulator of growth factor action in pancreatic carcinoma cells, and is overexpressed in human pancreatic cancer. J Clin Invest 102 (1998) 1662-1673
22. Ding K., Lopez-Burks M., Sanchez-Duran J.A., et al. Growth factor induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses to cancer cells. J Cell Biol 171 (2005) 729-738
23. Ketterer K., Rao S., Friess H., et al. RT-PCR analysis of laser-captured cells points to potential paracrine and autocrine actions of neurotrophins in pancreatic cancer. Clin Cancer Res 9 (2003) 5127-5136
24. Binkley C.E., Zhang L., Greenson J.K., et al. The molecular basis of pancreatic fibrosis: common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma. Pancreas 29 (2004) 254-263
25. Sato N., Maehara N., and Goggins M. Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res 64 (2004) 6950-6956
26. Fukahi K., Fukasawa M., Neufeld G., et al. Expression of neuropilins in pancreatic cancer. Clinical Cancer Res 10 (2004) 581-590
27. Koenig A., Mueller C., Hasel C., et al. Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. Cancer Res 66 (2006) 4662-4671
28. Hartel M., Di Mola F.F., Gardini A., et al. Desmoplastic reaction influences pancreatic cancer growth behavior. World J Surg 28 (2004) 818-825
29. Fukasawa M., and Korc M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res 10 (2004) 3327-3332
30. Rowland-Goldsmith M.A., Maruyama H., Kusama T., et al. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin Cancer Res 7 (2001) 2931-2940
31. Rowland-Goldsmith M.A., Maruyama H., Matsuda K., et al. Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Ther 1 (2002) 161-167
32. Friess H., Yamanaka Y., Büchler M.W., et al. Enhanced expression of transforming growth factor-beta isoforms in human pancreatic cancer correlates with decreased survival. Gastroenterology 105 (1993) 1846-1856
33. Aikawa T., Gunn J., Spong S.M., et al. Connective tissue growth factor specific antibody attenuates metastasis and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther 5 (2006) 1108-1116
34. Wenger C., Ellenrieder V., Alber B., et al. Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene 18 (1999) 1073-1080